Evogene
EVGN
29 hedge funds and large institutions have $1.25M invested in Evogene in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 12 closing their positions.
11% more call options, than puts
Call options by funds: $31K | Put options by funds: $28K
0.2% less ownership
Funds ownership: 0.59% → 0.39% (-0.2%)
24% less funds holding
Funds holding: 38 → 29 (-9)
55% less capital invested
Capital invested by funds: $2.8M → $1.25M (-$1.55M)
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$10K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$4.89K |
| 3 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$3.75K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.47K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$489 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$196K |
| 2 |
Morgan Stanley
New York
|
-$103K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$91.3K |
| 4 |
Jane Street
New York
|
-$85K |
| 5 |
Millennium Management
New York
|
-$79.5K |
EVGN Hedge Fund Activity: Q2 2022 in Review
29 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2022, worth a combined $1.25M — down 55% from $2.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of EVGN and 3 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 4 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $10K. The largest seller was Renaissance Technologies, cutting an estimated $196K.
- 29 institutional investors held Evogene (EVGN) as of Q2 2022, down from 38 in Q1 2022.
- Funds reported $1.25M of Evogene stock for Q2 2022, down 55% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q2 2022 and 12 closed out, a net change of -9 holders.
- The largest Evogene buyer in Q2 2022 was Two Sigma Securities, an estimated $10K added.
- The largest Evogene seller in Q2 2022 was Renaissance Technologies, an estimated $196K sold.
Based on aggregated 13F filings for Q2 2022.